STOCK TITAN

GSK plc (NYSE: GSK) plans Deloitte re-appointment as external auditor from 2028

(Neutral)
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

GSK plc announces that, following a competitive tender process led by its Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP as external auditor from the financial year ending 31 December 2028. Deloitte was initially appointed for the financial year ended 31 December 2018.

As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and rotate auditor every 20 years. A resolution to re-appoint Deloitte with effect from the 2028 financial year will be put to shareholders for approval at the 2028 Annual General Meeting, with further details to appear in GSK’s 2026 Annual Report.

Positive

  • None.

Negative

  • None.
Audit tender frequency every 10 years Requirement for GSK as a Public Interest Entity to tender statutory audit
Audit rotation requirement every 20 years Requirement for GSK as a Public Interest Entity to rotate external auditor
Start of new Deloitte term financial year ending 31 December 2028 Planned effective year of Deloitte’s re-appointment as external auditor
Initial Deloitte appointment year financial year ended 31 December 2018 Year Deloitte was first appointed as GSK’s external auditor
Public Interest Entity regulatory
"As a Public Interest Entity, GSK is required to tender the statutory audit"
statutory audit regulatory
"GSK is required to tender the statutory audit every 10 years"
competitive tender process financial
"after the conclusion of a competitive tender process led by the Audit & Risk Committee"
Annual General Meeting regulatory
"approval at the Company's 2028 Annual General Meeting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did GSK (GSK) decide regarding its external auditor?

GSK’s Board decided to re-appoint Deloitte LLP as its external auditor from the financial year ending 31 December 2028, following a competitive tender process led by the Audit & Risk Committee, subject to shareholder approval at the 2028 Annual General Meeting.

When will Deloitte’s re-appointment as GSK (GSK) auditor take effect?

Deloitte’s re-appointment is intended to take effect from GSK’s financial year ending 31 December 2028. A resolution for this re-appointment will be presented to shareholders for approval at the company’s 2028 Annual General Meeting.

What audit tender and rotation rules apply to GSK (GSK)?

As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and rotate its external auditor every 20 years. The competitive tender concluding in Deloitte’s planned re-appointment reflects these regulatory obligations.

When was Deloitte first appointed as GSK (GSK) external auditor?

Deloitte was first appointed as GSK’s external auditor with effect from the financial year ended 31 December 2018. The new decision extends that relationship, subject to shareholder approval, from the 2028 financial year onward.

How will GSK (GSK) shareholders approve Deloitte’s re-appointment?

A resolution to re-appoint Deloitte as GSK’s external auditor with effect from the 2028 financial year will be put to shareholders for approval at the company’s 2028 Annual General Meeting, in line with corporate governance practices.

Where will more details on GSK (GSK) audit tender be provided?

Further details of GSK’s competitive audit tender process will be included in the company’s 2026 Annual Report. This report is expected to describe the tender approach and considerations behind the Board’s decision to retain Deloitte.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of July 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Issued: 17 July 2026, London UK
 
Audit tender conclusion
  
 
GSK plc today announces that, after the conclusion of a competitive tender process led by the Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP (Deloitte) as GSK's external auditor from the financial year ending 31 December 2028.
 
As a Public Interest Entity, GSK is required to tender the statutory audit every 10 years and rotate every 20. The Company initially appointed Deloitte as external auditor with effect from the financial year ended 31 December 2018.
 
A resolution to re-appoint Deloitte as GSK's external auditor with effect from the 2028 financial year will be put to GSK's shareholders for approval at the Company's 2028 Annual General Meeting.
 
Further details of this competitive tender process will be included in GSK's 2026 Annual Report.
 
V A Whyte
Company Secretary
 
17 July 2026
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
 
Registered in England & Wales:
No. 3888792
  
Registered Office:
79 New Oxford Street
London
WC1A 1DG
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: July 17, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc